ESPE Abstracts (2019) 92 LB-15

Efficacy of 3-Monthly Compare to Monthly Depot GnRH Agonist (Triptorelin Pamoate) in the Treatment of Girls with Central Precocious Puberty in Korea

Lindsey Yoojin Chung, Rimm Huh, Hyo-Kyoung Nam, Young-Jun Rhie, Kee-Hyoung Lee


Korea University College of Medicine, Department of Pediatrics, Seoul, Korea, Republic of


Background: Triptorelin depot is largely used to treat central precocious puberty (CPP) in children and currently 3 monthly depot was introduced. No Korean data are available on 3-monthly GnRH agonist treatment in central precocious puberty.

Aim: To compare the efficacy of Triptorelin 11.25mg 3-months depot with 3.75mg monthly depot in suppressing pubertal development from the beginning to 6 month and 1 year after the treatment of central precocious puberty

Methods: A retrospective study of 89 patients with Central precocious puberty treated with Triptorelin pamoate from 2015 to 2018 was conducted in the pediatric endocrinology clinic of Korea University Medical Center, Korea. 50 patients out of 89 were treated with Triptorelin 11.25mg 3-monthly depot and 39 patients were treated with Triptorelin 3.75mg monthly depot. Level of serum LH, FSH and estradiol was analyzed to compare the level of suppression of hypothalamus-pituitary-gonadal axis of each depot. Pubertal score, height and bone age were evaluated at the beginning, after the 6 months and one year of both therapies.

Results: The baseline characteristics of patients treated with 3-monthly depot were similar to those of patients treated with monthly depot. A suppressed luteinizing hormone (LH) response (peak LH ≤3IU/L) to the GnRH test at 6 months occurred in 93.3% and 100% of the cases in patients treated with 3-monthly and monthly depot respectively. At 1 year after treatment, a suppressed LH response occurred in 96.2% and 100% of the cases in patients treated with 3-monthly and monthly depot respectively. Pubertal development was slowed in both patients. Degree of bone age advancement was decreased from 1.85±0.51 and 1.86±0.52 at beginning to 1.66±0.60 and 1.75±0.59 in patients treated with 3-monthly and monthly depot for 6 months respectively and to 1.26±0.47 and 1.60±0.55 in patients treated with 3-monthly and monthly depot for 1 year respectively.

Conclusion: Triptorelin pamoate 11.25mg 3-monthly depot is an effective treatment in patients with central precocious puberty. The efficacy for slowing pubertal development and reducing bone age advancement appear similar to both monthly depot and 3-monthly depot.

Article tools

My recent searches

No recent searches.